PrecisionMed

PrecisionMed is a long-established, revenue-generating services company that provides critical human biological materials to accelerate research in diagnostics, genetics, and biomarker discovery. Its core strength lies in its predictive biobanking model, which maintains a robust, immediately available inventory of high-quality samples, most notably claiming the world's largest private commercial CSF biorepository. Acquired by BioIVT, the company serves a global clientele of top pharmaceutical companies, biotech firms, and academic institutions, supporting research timelines by reducing the resource-intensive process of sample collection and characterization. Its business is built on a guaranteed quality model, regulatory compliance, and full transfer of sample rights to the customer.

Predictive biobanking platform utilizing a validated network of clinical sites for standardized collection of longitudinal human biospecimens (CSF, plasma, tissue) with matched clinical data. Focus on immediate availability, rigorous quality control, and full transfer of sample rights to the customer.

PrecisionMed competes in the commercial biospecimen market with other providers like Discovery Life Sciences, as well as academic and non-profit biobanks. Its claimed dominance in commercial CSF inventory and its 'immediate availability' model are key differentiators. As part of BioIVT, it now competes at a larger scale against integrated research model and specimen providers.